Moderator: ofonorow
ofonorow wrote:Well, since there haven't been ANY studies with dosages even close to Pauling's recommended dosages other than the "lost" Kale Kenton study, and perhaps Matthias Rath's on his own products, (however, his products were quite low in dosages) shouldn't the aim should be to have it run and published (rather than worrying about whether it will be widely accepted?)
There are also ethical reasons behind wanting to change the placebo paradigm. Many alternative doctors would consider it unethical to deprive patients of a treatment they know works.
But the central problem is the general availability of vitamin C at any drug store. If I am a typical subject in a long term study, and I determine that I am not in the vitamin C group, the heck with the study. I'll take my own vitamin C.
Since this is a thought experiment, why not bat around the idea of the initial baseline. (I am assuming that all patients would be either stable, or declining from all measures during this initial measuring period. ) If, as I predict, all patients begin improving after the introduction of Pauling's protocol, perhaps at different rates, I don't see why you couldn't run statistical analysis against the baseline. This would also provide more knowledge, as every patient would have different dosage requirements, and thus would be predicted to improve at a different rate from the others.
I don't see a downside from making all subjects their own control.
(Investigative Ophthalmology and Visual Science. 2006;47:2341-2350.)
© 2006 by The Association for Research in Vision and Ophthalmology, Inc.
DOI: 10.1167/iovs.05-1539
This Article
Google Scholar
Articles by Wong, T. Y.
Articles by Shahar, E.
Search for Related Content
PubMed
PubMed Citation
Articles by Wong, T. Y.
Articles by Shahar, E.
Retinal Vascular Caliber, Cardiovascular Risk Factors, and Inflammation: The Multi-Ethnic Study of Atherosclerosis (MESA)
Tien Yin Wong,1,2 F. M. Amirul Islam,1 Ronald Klein,3 Barbara E. K. Klein,3 Mary Frances Cotch,4 Cecilia Castro,5 A. Richey Sharrett,6 and Eyal Shahar7
Measuring retinal vessel tortuosity in 10 year old children:
validation of the Computer Assisted Image Analysis of the Retina
(CAIAR) program
Authors
Christopher G Owen PhD1, Alicja R Rudnicka PhD1, Robert Mullen MRes2, Sarah A Barman
PhD2, Dorothy Monekosso PhD2, Peter H Whincup FFPH1, Jeffrey Ng PhD3, Carl Paterson
PhD4
An example is idiopathic thrombocytopenic purpura (ITP). It can be treated, but generally the results are not very good. A few years ago, a professor of medicine advised one of his female patients that he could not help her. She came back one month later, and she was well. This doctor must surely have been shocked; but unlike many doctors, he was curious. She told him she had been advised by a health store salesperson to take vitamin C – one gram each day. The doctor must have been even more shocked (but not out of his mind), and he decided to try it on another patient. The second patient also recovered. Eventually, he treated eight patients successfully. Since the usual recovery rate was zero and he had seen 100% recovery, he wrote a paper and submitted it to the New England Journal of Medicine. It was rejected. They demanded a double-blind, controlled trial.
Smith and Pell published the results of a literature search to see if parachutes really do prevent death and major trauma. We all believe that this is self-evident and true. But they were unable to find any randomized controlled trials of parachute intervention. It is evident that we do accept self-evident phenomena without demanding the holy double-blind. Smith and Pell concluded, “As with many interventions intended to prevent ill health, effectiveness of parachutes has not been subjected to rigorous evaluation by using randomized, controlled trials. Advocates of evidence-based medicine have criticized the adoption of interventions evaluated by using only observational data. We think that most everyone might benefit if the most radical protagonist of evidence-based medicine organized and participated in a double-blind, randomized placebo-controlled, cross-over trial of the parachute.”
Return to “Heart Disease: Linus Pauling's Vitamin C/Lysine Therapy”
Users browsing this forum: No registered users and 47 guests